| Leukemia |
| Terminated | 1 | 97 | Europe, US | ME-401, Rituximab, Rituxan, Zanubrutinib | MEI Pharma, Inc. | Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Follicular Lymphoma (FL), Marginal Zone B Cell Lymphoma, Diffuse Large B-cell Lymphoma (DLBCL), High Grade Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma (MCL) | 03/23 | 03/23 | | |
NCT04626765: CAR-T for Children With Relapsed and Refractory Acute Lymphoblastic Leukemia |
|
|
| Recruiting | 1 | 50 | RoW | CD19 CAR-T, Senl_19, CD22 CAR-T, Senl_22, CD 19+22, Senl_19+22, Fludarabine, flu, Cyclophosphamide, ctx | Hebei Senlang Biotechnology Inc., Ltd., The Second Hospital of Hebei Medical University | Childhood Acute Lymphoblastic Leukemia | 03/23 | 05/23 | | |
NCT03884829: A Phase I Study of CYC140, a PLK-1 Inhibitor, in Advanced Leukemias or MDS |
|
|
| Recruiting | 1 | 50 | US | CYC140 | Cyclacel Pharmaceuticals, Inc., M.D. Anderson Cancer Center | AML, Adult, Myelodysplastic Syndromes, ALL, Adult, CML, Refractory, CLL, Refractory | 04/23 | 09/23 | | |
NCT04017546: CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory AML or MDS |
|
|
| Completed | 1 | 14 | US | CYC065, Venetoclax | Cyclacel Pharmaceuticals, Inc., M.D. Anderson Cancer Center | AML, MDS | 11/22 | 04/23 | | |
NCT02848001: A Dose-finding Study of CC-90009 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-risk Myelodysplastic Syndromes |
|
|
| Terminated | 1 | 101 | Europe, Canada, US | CC-90009 | Celgene | Leukemia, Myeloid, Acute, Myelodysplastic Syndromes | 04/23 | 04/24 | | |
NCT03236857 / 2017-000439-14: A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies |
|
|
| Completed | 1 | 143 | Europe, Canada, US, RoW | chemotherapy, venetoclax, ABT-199, GDC-0199, Venclexta | AbbVie, Roche-Genentech | Malignancies, Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Non-Hodgkin's Lymphoma, Neuroblastoma | 04/23 | 04/23 | | |
| Active, not recruiting | 1 | 316 | Europe, US | LOXO-338, LY3847429, Pirtobrutinib, LOXO-305, LY3527727 | Eli Lilly and Company, Loxo Oncology, Inc. | Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-cell Marginal Zone, Lymphoma, Non-Hodgkin, Multiple Myeloma, B-cell Lymphoma, Waldenstrom Macroglobulinemia, Lymphoma, Mantle-Cell | 06/23 | 12/24 | | |
CARTHIAE-1, NCT05705570: A Phase I Clinical Trial Using Genetically Engineered Autologous T Cells to Express Chimeric Antigen Receptor (CAR) for Treatment of Patients With Refractory or Relapsed CD19-positive B Lymphoid Malignancies |
|
|
| Not yet recruiting | 1 | 30 | RoW | Cyclophosphamide, Fludarabine, Chimeric antigen receptor T cells to be implemented in a "3 + 3" design on day 0 | Hospital Israelita Albert Einstein, Miltenyi Biotec, Inc. | Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia Refractory, B-cell Lymphoma Recurrent, B-cell Lymphoma Refractory, Chronic Lymphocytic Leukemia Recurrent, Chronic Lymphocytic Leukemia Refractory | 05/23 | 12/28 | | |
NCT05244070: A Study to Evaluate the Safety and Tolerability of BMS-986403 in Participants With Relapsed and/or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma |
|
|
| Terminated | 1 | 5 | Europe, US | BMS-986403, Fludarabine, Cyclophosphamide | Bristol-Myers Squibb | Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma | 05/23 | 05/23 | | |
NCT04912063: Study to Evaluate Adverse Events and Movement of Lemzoparlimab in Body When Used Intravenously (IV) With Azacitidine Subcutaneously or IV and Venetoclax Orally in Participants With Acute Myeloid Leukemia and With Azacitidine With or Without Venetoclax in Participants With Myelodysplastic Syndrome |
|
|
| Terminated | 1 | 40 | Europe, Japan, US, RoW | Lemzoparlimab, TJ011133, ABBV-IMAB-TJC4, Azacitidine, Venetoclax, Venclexta, Venclyxto, ABT-199, GDC-0199 | AbbVie | Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS) | 05/23 | 05/23 | | |
NCT04626726: Adult B-ALL Treated by CART Cell Bridging Allogeneic Hematopoietic Stem Cell Transplantation |
|
|
| Recruiting | 1 | 50 | RoW | CD19 CAR-T, Senl_19, CD22 CAR-T, Senl_22, CD19+CD22 CAR-T, Senl_19+22, Fludarabine, fiu, Cyclophosphamide, ctx | Hebei Senlang Biotechnology Inc., Ltd. | Adult B Acute Lymphoblastic Leukemia | 05/23 | 05/23 | | |
NCT04934774: Non-gene Edited Anti-CD7 CAR T Cells for Relapsed/Refractory T Cell Malignances |
|
|
| Recruiting | 1 | 20 | RoW | CD7 CAR T cells | iCell Gene Therapeutics, iCAR Bio Therapeutics Ltd., Peking University Shenzhen Hospital | T-cell Acute Lymphoblastic Leukemia, T-cell Acute Lymphoblastic Lymphoma, T-cell Non-Hodgkin Lymphoma | 06/23 | 06/23 | | |
NCT04766840: Donor-derived CAR-T Cells in the Treatment of AML Patients |
|
|
| Not yet recruiting | 1 | 9 | RoW | CAR-T cells, IM73 CAR-T Cells | Beijing Immunochina Medical Science & Technology Co., Ltd. | AML | 06/23 | 12/23 | | |
NCT05432401: TAA05 Injection in the Treatment of Adult Patients With FLT3-positive Relapsed/Refractory Acute Myeloid Leukemia |
|
|
| Recruiting | 1 | 18 | RoW | T cell injection targeting FLT3 chimeric antigen receptor, TAA05 Injection | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | FLT3-positive Relapsed/Refractory Acute Myeloid Leukemia | 06/23 | 06/25 | | |
NCT05223686: To Evaluate the Safety and Tolerability of Human CD19-CD22 Targeted T Cells Injection for Subjects With R/R B-ALL. |
|
|
| Not yet recruiting | 1 | 18 | RoW | Human CD19-CD22 Targeted T Cells Injection, CD19-CD22 CAR-T | Hrain Biotechnology Co., Ltd., Ruijin Hospital | Acute Lymphoblastic Leukemia | 06/23 | 03/25 | | |
| Recruiting | 1 | 60 | US | LP-168 | Newave Pharmaceutical Inc | CLL/SLL, Waldenstrom Macroglobulinemia, Follicular Lymphoma, Diffuse Large B Cell Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Hairy Cell Leukemia | 07/25 | 12/25 | | |
NCT04603001: Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations |
|
|
| Active, not recruiting | 1 | 260 | Europe, Canada, US, RoW | LY3410738, Venetoclax, Azacitidine | Eli Lilly and Company, Loxo Oncology, Inc. | Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Chronic Myelomonocytic Leukemia (CMML), Myeloproliferative Neoplasms (MPNs) | 07/23 | 05/25 | | |
NCT03755154: Study of a New Intravenous Drug, Called S65487, in Patients With Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma or Chronic Lymphocytic Leukemia |
|
|
| Completed | 1 | 60 | Europe, RoW | S65487- initial scheme, S65487 - alternative scheme | Institut de Recherches Internationales Servier, ADIR, a Servier Group company | Relapsed or Refractory Acute Myeloid Leukemia, Relapsed or Refractory Non-Hodgkin Lymphoma, Relapsed or Refractory Multiple Myeloma, Relapsed or Refractory Chronic Lymphocytic Leukemia | 11/23 | 11/23 | | |
SELCLAX, NCT04898894: Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia |
|
|
| Recruiting | 1 | 42 | US | Venetoclax, Venclextra®, ABT-199, Selinexor, KPT-330, Cytarabine, Cytosine arabinoside, Ara-C, Cytosar®, Fludarabine, Fludara®, Fludarabine phosphate, 2-fluoro-ara-AMP, Filgrastim, G-CSF, Methotrexate, MTX, amethopterin, Trexall®, methotrexate/hydrocortisone/cytarabine, ITMHA, Intrathecal triples | St. Jude Children's Research Hospital, Karyopharm Therapeutics Inc, AbbVie, Gateway for Cancer Research | Acute Leukemia of Ambiguous Lineage in Relapse, Acute Myeloid Leukemia, in Relapse, Refractory Acute Leukemia of Ambiguous Lineage, Refractory Acute Myeloid Leukemia | 07/23 | 07/25 | | |
NCT04614636: FT538 in Subjects With Advanced Hematologic Malignancies |
|
|
| Terminated | 1 | 42 | US | FT538, Cyclophosphamide, Fludarabine, Daratumumab, Darzalex, Elotuzumab, Empliciti | Fate Therapeutics | Acute Myeloid Leukemia, AML, Adult, Multiple Myeloma, Myeloma | 07/23 | 08/23 | | |
ALL 001, NCT03962465: Phase I Study of Inotuzumab With Augmented BFM Re-Induction for Patients With Relapsed/Refractory B-cell ALL |
|
|
| Active, not recruiting | 1 | 36 | US | Inotuzumab ozogamicin, Besponsa, Prednisone Pill, Deltasone, Daunorubicin, Cerubidine, daunomycin, rubidomycin, Vincristine, Oncovin, Vincasar, Leurocristine, Cytarabine, Ara-C, Cytosar-U, Methotrexate, Otrexup, Rasuvo, Rheumatrex, Trexall, MTX, Amethopterin, Pegaspargase, Oncospar | University of Virginia, Pfizer, Vanderbilt University, University of Wisconsin, Madison, Virginia Commonwealth University | B-cell Acute Lymphoblastic Leukemia | 07/23 | 07/26 | | |
NCT03654716: Phase 1 Study of the Dual MDM2/MDMX Inhibitor ALRN-6924 in Pediatric Cancer |
|
|
| Completed | 1 | 21 | US | ALRN-6924, Cytarabine, Cytosar | Dana-Farber Cancer Institute, TeamConnor Childhood Cancer Foundation, Cookies for Kids' Cancer, Aileron Therapeutics, Inc. | Leukemia, Brain Tumor, Solid Tumor, Lymphoma | 07/23 | 07/23 | | |
NCT04402541: Study of CB-5339 in Acute Myeloid Leukemia or Myelodysplastic Syndrome |
|
|
| Completed | 1 | 55 | US, RoW | CB-5339, CB-5339 Tosylate | Cleave Therapeutics, Inc. | Acute Myeloid Leukemia, in Relapse, Myelodysplastic Syndromes | 07/23 | 07/23 | | |
NCT03064269: CAR-T Therapy for Central Nervous System B-cell Acute Lymphocytic Leukemia |
|
|
| Recruiting | 1 | 10 | RoW | CD19 CAR-T cells | Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd, The First Affiliated Hospital of Soochow University | B-cell Acute Lymphocytic Leukemia | 12/24 | 12/25 | | |
NCT03422393: Venetoclax With High-dose Ibrutinib for CLL Progressing on Single Agent Ibrutinib |
|
|
| Active, not recruiting | 1 | 24 | US | Venetoclax, Venclexta, Ibrutinib, Imbruvica | Michael Choi, Pharmacyclics LLC. | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 08/23 | 08/28 | | |
NCT05225831: Safety and Efficacy of CD19/CD22 Dual Targeted CAR-T Cell Therapy in R/R B-Cell Acute Lymphoblastic Leukemia |
|
|
| Recruiting | 1 | 100 | RoW | Autologous CD19/CD22 Chimeric Antigen Receptor T-cells, SL19+22 CAR-T, Cyclophosphamide,Fludarabine | Hebei Senlang Biotechnology Inc., Ltd., Hebei Yanda Ludaopei Hospital | CD19+ and CD 22+ B-ALL | 08/23 | 11/23 | | |
NCT04100187: Immunotherapy With CD19 CAR T-cells for B-Cell Leukemia |
|
|
| Not yet recruiting | 1 | 100 | NA | Anti-CD19-CAR | Kecellitics Biotech Company Ltd, Hebei Yanda Ludaopei Hospital | Leukemia | 08/23 | 08/24 | | |
NCT04532268: A Study of Humanized CD19 CAR-T Cells Therapy for Patients With Relapsed and/or Refractory B-cell ALL and B-cell NHL |
|
|
| Recruiting | 1 | 72 | RoW | Humanized CD19 CAR-T cells, Humanized CD19 CAR-T cells injection | Zhejiang University, Yake Biotechnology Ltd. | Acute Lymphoblastic Leukemia, Non-hodgkin Lymphoma,B Cell | 08/23 | 08/26 | | |
NCT04980404: Inqovi Maintenance Therapy in Myeloid Neoplasms |
|
|
| Recruiting | 1 | 22 | US | Inqovi, decitabine, cedazuridine | Massachusetts General Hospital, Taiho Oncology, Inc. | Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Stem Cell Leukemia | 08/23 | 08/24 | | |
NCT04806659: A Phase 1 Study of SH1573 Capsules in Subjects With Refractory or Relapsed Acute Myelogenous Leukemia |
|
|
| Recruiting | 1 | 41 | RoW | SH1573 Capsules | Nanjing Sanhome Pharmaceutical, Co., Ltd. | Acute Myelogenous Leukemia | 08/23 | 12/23 | | |
BISECT, NCT05456269: A Study of Bisantrene Combined With Cytarabine or With Decitabine for Adult Subjects With Extramedullary AML and MDS |
|
|
| Withdrawn | 1 | 60 | RoW | Bisantrene Dihydrochloride (high dose), RC110, Zantrene®, Xantrene®, Bisantrene Dihydrochloride (low dose), Cytarabine Hydrochloride, Ara-C, Cytarabine arabinoside, Cytosar-U®, Decitabine and cedazuridine, ASTX727 | Race Oncology Ltd, Astex Pharmaceuticals, Inc. | Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, Higher Risk Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia | 08/23 | 08/23 | | |
waveLINE-001, NCT03833180: A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001) |
|
|
| Completed | 1 | 91 | US | Zilovertamab vedotin, VLS-101, MK-2140 | VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma, Diffuse Large B-cell Lymphoma, Richter Transformation Lymphoma, Burkitt Lymphoma, Lymphoplasmacytoid Lymphoma, T-cell Non-Hodgkin Lymphoma, Acute Lymphoid Leukemia, Acute Myeloid Leukemia, Waldenstrom Macroglobulinemia | 12/23 | 12/23 | | |
NCT03571321: Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia |
|
|
| Recruiting | 1 | 15 | US | Ruxolitinib, Jakafi, Cyclophosphamide, Cytarabine, Mercaptopurine, Vincristine, Pegaspargase, Rituximab, Methotrexate (Intrathecal Administration), Methotrexate (Intravenous Administration), Dexamethasone, Doxorubicin, Thioguanine, Methotrexate Oral Product | University of Chicago, Incyte Corporation | Acute Lymphoblastic Leukemia, ALL, Childhood, ALL | 09/26 | 09/27 | | |
NCT05426798: Clinical Study of TQB2618 Injection in Combination With Demethylation Drugs in Patients With Recurrent/Refractory Acute Myeloid Leukemia, Myelodysplastic Syndromes |
|
|
| Recruiting | 1 | 73 | RoW | TQB2618 injection azacitidine, AZA decitabine, DAC | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Recurrent/Refractory Acute Myeloid Leukemia, Myelodysplastic Syndromes | 09/23 | 12/23 | | |
NCT05144334: A Study of BTX-1188 in Subjects With Advanced Malignancies |
|
|
| Terminated | 1 | 8 | US | BTX-1188 | BioTheryX, Inc. | Advanced Solid Tumor, Non Hodgkin Lymphoma, Acute Myeloid Leukemia | 09/23 | 09/23 | | |
NCT03720366: A Study of Perpetrator Drug Interactions of Enasidenib in AML Patients |
|
|
| Completed | 1 | 40 | RoW | enasidenib, CC-90007, AG-221, Arm 1 probes, Arm 2 Probes, Arm 3 probes | Celgene | Leukemia, Myeloid, Acute | 09/23 | 12/23 | | |
NCT05731219: UTAA06 Injection in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia |
|
|
| Recruiting | 1 | 18 | RoW | B7-H3 target, CAR gene modified gdT cell injection, UTAA06 injection | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | Relapsed/Refractory Acute Myeloid Leukemia | 09/23 | 09/25 | | |
NCT04245722: FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies |
|
|
| Terminated | 1 | 98 | US | FT596, Cyclophosphamide, Fludarabine, Rituximab, Rituxan, Truxima, Ruxience, Obinutuzumab, Gazyva, Bendamustine, Bendeka, Treanda | Fate Therapeutics | Lymphoma, B-Cell, Chronic Lymphocytic Leukemia | 09/23 | 09/23 | | |
NCT02957032: A Study of the Tumor-targeting Human F16IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Very Low-dose Cytarabine in Patients With AML Relapse After Allogeneic Hematopoietic Stem Cell Transplantation |
|
|
| Terminated | 1 | 30 | Europe | F16IL2, cytarabine | Philogen S.p.A. | Acute Myeloid Leukemia, Relapsed, Adult | 09/23 | 09/23 | | |
NCT03893682: A Study of CG-806 in Patients With Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas |
|
|
| Active, not recruiting | 1 | 160 | US | CG-806, Luxeptinib | Aptose Biosciences Inc. | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Non-Hodgkin's Lymphoma | 02/24 | 12/24 | | |
NCT04070768: Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (GO) and Venetoclax in Patients With Relapsed or Refractory CD33+ Acute Myeloid Leukemia:Big Ten Cancer Research Consortium BTCRC-AML17-113 |
|
|
| Active, not recruiting | 1 | 18 | US | Gemtuzumab Ozogamicin, GO, Venetoclax | John Quigley, Pfizer, AbbVie | Acute Myeloid Leukemia | 10/23 | 10/24 | | |
NCT04477291: A Study of CG-806 in Patients With Relapsed or Refractory AML or Higher-Risk MDS |
|
|
| Active, not recruiting | 1 | 80 | US | CG-806 | Aptose Biosciences Inc. | Acute Myeloid Leukemia, Myelodysplastic Syndromes | 02/24 | 12/24 | | |
NCT05961696: A Phase I Study of Mosunetuzumab for Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia |
|
|
| Withdrawn | 1 | 22 | US | Mosunetuzumab, RO7030816 | M.D. Anderson Cancer Center, Genentech, Inc. | Refractory B-cell Acute Lymphoblastic Leukemia | 10/23 | 10/23 | | |
NCT05712278: A Study to Investigate Use of Off-the-shelf Natural Killer (NK) Cells (SAR445419) in Relapsed/Refractory Acute Myeloid Leukemia |
|
|
| Terminated | 1 | 7 | US | SAR445419, fludarabine, fludara, cytarabine, cytosar-U | Sanofi | Acute Myeloid Leukaemia | 02/24 | 03/24 | | |
NCT04336982: A Safety and Efficacy Study of CC-90009 Combinations in Subjects With Acute Myeloid Leukemia |
|
|
| Terminated | 1 | 22 | Europe, Canada, US | CC-90009, Venetoclax, Azacitidine, Gilteritinib | Celgene, AbbVie | Leukemia, Myeloid, Acute | 10/23 | 04/24 | | |
NCT03760523: Dose Escalation Study of Minnelide in Relapsed or Refractory Acute Myeloid Leukemia |
|
|
| Terminated | 1 | 27 | US | Minnelide | H. Lee Moffitt Cancer Center and Research Institute, Minneamrita Therapeutics LLC | Acute Myeloid Leukemia | 10/23 | 10/23 | | |
JSP-CP-003, NCT04429191: JSP191 Antibody Conditioning Regimen in MDS/AML Subjects Undergoing Allogenic Hematopoietic Stem Cell Transplantation |
|
|
| Recruiting | 1 | 40 | US | Humanized anti-CD117 Monoclonal Antibody (JSP191), JSP191 | Jasper Therapeutics, Inc. | MYELODYSPLASTIC SYNDROME; MDS, ACUTE MYELOID LEUKEMIA; AML | 10/23 | 12/23 | | |
| Active, not recruiting | 1 | 25 | US | FLUDARABINE, Fludara®, CYCLOPHOSPHAMIDE, Cytoxan®, Neosar®, TBI, Melphalan, Alkeran®, L-PAM, L-Sarcolysin, Phenylalanine Mustard, Sirolimus, Rapamune, Mycophenolate mofetil, CellCept, Myfortic, RGI-2001 | Zachariah Michael DeFilipp, Regimmune Corporation | GVHD, AML, ALL, MDS, MPN, CMML, Hodgkin Lymphoma, Non Hodgkin Lymphoma, Blood Stem Cell Transplant Failure, Graft Vs Host Disease, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorder, Chronic Myelomonocytic Leukemia, Chemosensitive Hodgkin Lymphoma | 10/23 | 10/24 | | |
| Terminated | 1 | 72 | US | FT516, Rituximab, Rituxan, MabThera, Obinutuzumab, Gazyva, Cyclophosphamide, Fludarabine, IL-2, Bendamustine, Bendeka, Treanda | Fate Therapeutics | Acute Myelogenous Leukemia, B-cell Lymphoma | 10/23 | 10/23 | | |
NCT03900598: A Study of JNJ-67856633 in Participants With Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) |
|
|
| Active, not recruiting | 1 | 226 | Europe, Japan, US, RoW | JNJ-67856633 | Janssen Research & Development, LLC | Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Non-Hodgkin | 12/24 | 01/26 | | |
NCT04540796: A Study of JNJ-75348780 in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) |
|
|
| Active, not recruiting | 1 | 147 | Europe, US, RoW | JNJ-75348780 | Janssen Research & Development, LLC | Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell | 04/25 | 05/25 | | |
NCT04628338: IFN-γ to Treat Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) That Has Relapsed After Allogeneic Hematopoietic Stem Cell Transplantation |
|
|
| Completed | 1 | 8 | US | IFN-γ (interferon gamma-1b) injection, ACTIMMUNE® | Sawa Ito, MD, Horizon Pharma USA, Inc. | Myelodysplastic Syndromes, Myeloid Leukemia, Allogeneic Stem Cell Transplantation | 10/23 | 10/23 | | |
NCT05727683: CD19-targeted CAR T Cells for Patients With Relapsed or Refractory in B-cell Acute Lymphoblastic Leukemia |
|
|
| Recruiting | 1 | 33 | RoW | CD19-targeted Chimeric Antigen Receptor (CAR) T Cells, Fludarabine, Cyclophosphamide | Shanghai Ming Ju Biotechnology Co., Ltd. | Acute Lymphocytic Leukemia | 10/23 | 07/25 | | |
NCT03595917: ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML |
|
|
| Recruiting | 1 | 40 | US | ABL001, Dasatinib, Sprycel, Prednisone, Blinatumomab | Marlise Luskin, MD, Novartis | B-cell Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia (CML) in Lymphoid Blast Crisis, Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Ph+ ALL | 11/25 | 11/26 | | |
NCT04532281: A Study of Murine CD19 CAR-T Therapy for Patients With Relapsed or Refractory CD19+ B-cell Hematological Malignancies |
|
|
| Recruiting | 1 | 120 | RoW | Murine CD19 CAR-T cells, Murine CD19 CAR-T cells injection | Zhejiang University, Yake Biotechnology Ltd. | Acute Lymphoblastic Leukemia, Non-Hodgkin Lymphoma of Soft Tissue | 11/23 | 11/26 | | |
NCT04603872: CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignancies |
|
|
| Recruiting | 1 | 120 | RoW | CD19/BCMA Targeted CAR T-cells and dasatinib, Administration of CD19/BCMA Targeted CAR T-cells and dasatinib, CD19/BCMA Targeted CAR T-cells, CD19/BCMA Targeted CAR T-cells infusion | Zhejiang University, Yake Biotechnology Ltd. | Multiple Myeloma in Relapse, Multiple Myeloma, Refractory, Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphocytic Leukaemia Refractory, Non-Hodgkin's Lymphoma, Relapsed, Non-Hodgkin's Lymphoma Refractory | 11/23 | 11/26 | | |
NCT04876092: A Study of the MALT1 Inhibitor JNJ-67856633 and Ibrutinib in Combination in B-cell NHL and CLL |
|
|
| Active, not recruiting | 1 | 45 | Europe | JNJ-67856633, Ibrutinib, JNJ-54179060 | Janssen Research & Development, LLC | Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Non-Hodgkin | 11/24 | 11/24 | | |
NCT04599543: IL3 CAR-T Cell Therapy for Patients With CD123 Positive Relapsed and/or Refractory Acute Myeloid Leukemia |
|
|
| Not yet recruiting | 1 | 36 | RoW | IL3 CAR T-cells, IL3 CAR-T cells injection | Zhejiang University, Yake Biotechnology Ltd. | Acute Myeloid Leukemia | 11/23 | 11/26 | | |
NCT04609241: CD79b CAR-T Cell Therapy for Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia and B-cell Non-Hodgkin's Lymphoma |
|
|
| Not yet recruiting | 1 | 72 | RoW | CD79b CAR-T Cells | Zhejiang University, Yake Biotechnology Ltd. | Relapsed and/or Refractory Acute Lymphoblastic Leukemia, Relapsed and/or Refractory B-cell Non-Hodgkin's Lymphoma | 11/23 | 11/26 | | |
AUTO1-PY1, NCT06173518: A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL) |
|
|
| Recruiting | 1 | 24 | Europe, US | AUTO1, Obecabtagene autoleucel (obe-cel) | Autolus Limited | Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia, Relapsed or Refractory B Cell Non-Hodgkin Lymphoma | 11/27 | 11/27 | | |
| Recruiting | 1 | 20 | RoW | anti-CD5 CAR T cells | iCell Gene Therapeutics, iCAR Bio, Peking University Shenzhen Hospital | T-cell Acute Lymphoblastic Leukemia, T-cell Non-Hodgkin Lymphoma | 11/23 | 11/23 | | |
NCT00819546: RAD001 in Combination With PKC412 in Patients With Relapsed, Refractory or Poor Prognosis AML or MDS |
|
|
| Active, not recruiting | 1 | 29 | US | RAD001, everolimus, PKC412, midostaurin | Richard Stone, MD, Beth Israel Deaconess Medical Center, Massachusetts General Hospital, Brigham and Women's Hospital, Novartis | Acute Myeloid Leukemia, Myelodysplastic Syndrome | 12/25 | 12/25 | | |
|
NCT03063944: STAT Inhibitor OPB-111077, Decitabine and Venetoclax in Treating Patients With Acute Myeloid Leukemia That Is Refractory, Relapsed or Newly Diagnosed and Ineligible for Intensive Chemotherapy |
|
|
| Completed | 1 | 37 | US | STAT Inhibitor OPB-111077, OPB-111077, Decitabine, 2'-Deoxy-5-azacytidine, 4-Amino-1-(2-deoxy-beta-D-erythro-pentofuranosyl)-1,3,5-triazin-2(1H)-one, 2353-33-5, 5-Aza-2'-deoxycytidine, 5-Aza-2'deoxycytidine, 5-Aza-2-deoxycytidine, 5-Azadeoxycytidine, Dacogen, Decitabine for Injection, Deoxyazacytidine, Dezocitidine, Venetoclax, 1257044-40-8, 4-(4-((2-(4-Chlorophenyl)-4, 4-dimethylcyclohex-1-en-1-yl)methyl)piperazin-1-yl)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)-2-(1H-pyrrolo(2,3-b)pyridin-5-yloxy)benzamide, ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta, Venclyxto, Laboratory Biomarker Analysis | Sidney Kimmel Cancer Center at Thomas Jefferson University, Otsuka America Pharmaceutical | Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia | 01/24 | 03/24 | | |
NCT03740334: Ribociclib in Combination With Everolimus and Dexamethasone in Relapsed ALL |
|
|
| Active, not recruiting | 1 | 45 | US | Ribociclib, LEE011, Dexamethasone, Everolimus, Zortress | Dana-Farber Cancer Institute, Novartis | Acute Lymphoblastic Leukemia ALL | 03/23 | 09/24 | | |
PBCAR0191-01, NCT03666000: Dose-escalation, Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Patients With r/r NHL and r/r B-cell ALL |
|
|
| Recruiting | 1 | 129 | US | Azer-cel, Allogeneic Anti-CD19 CAR T cells, PBCAR0191, Fludarabine, Cyclophosphamide, IL-2, Bendamustine | Imugene Limited | Non-Hodgkin Lymphoma, B-cell Acute Lymphoblastic Leukemia | 03/26 | 03/28 | | |
NCT03955783: Venetoclax and Selinexor in Treating Patients With Relapsed or Refractory High Risk Hematologic Malignancies |
|
|
| Active, not recruiting | 1 | 78 | US | Venetoclax, Selinexor | Sanjay Mohan, Karyopharm Therapeutics Inc, AbbVie | Diffuse Large B-cell Lymphoma, Acute Myeloid Leukemia, Non-Hodgkin's Lymphoma | 09/24 | 12/24 | | |
NCT03940352: HDM201 in Combination With MBG453 or Venetoclax in Patients With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS) |
|
|
| Active, not recruiting | 1 | 52 | Europe, US, RoW | HDM201, MBG453, Venetoclax | Novartis Pharmaceuticals | Acute Myeloid Leukemia (AML), High-risk Myelodysplastic Syndrome (MDS) | 06/24 | 06/24 | | |
NCT04034446: CD19-CD22 Chimeric Antigen Receptor T (CAR-T) Cell for Treatment of B Cell Acute Lymphoblastic Leukemia (B-ALL) |
|
|
| Active, not recruiting | 1 | 2 | RoW | CD19-CD22 CAR-T cells | Institute of Hematology & Blood Diseases Hospital, Juventas Cell Therapy Ltd. | Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia | 12/23 | 12/23 | | |
| Active, not recruiting | 1 | 30 | US, RoW | BR101801 (Phase Ia), BR101801 (Phase Ib) | Boryung Pharmaceutical Co., Ltd | Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, B Cell Lymphoma, Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia, Peripheral T Cell Lymphoma | 09/23 | 03/24 | | |
| Recruiting | 1 | 74 | RoW | LP-108 tablet | The First Affiliated Hospital with Nanjing Medical University, Guangzhou Lupeng Pharmaceutical Company LTD., Newave Pharmaceutical Inc | Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia | 12/23 | 12/23 | | |
| Recruiting | 1 | 106 | US | IO-202, IO-202 and Azacitidine, IO-202 and AZA, IO-202 and Azacitidine + Venetoclax, IO-202 and AZA + Ven | Immune-Onc Therapeutics, California Institute for Regenerative Medicine (CIRM) | AML With Monocytic Differentiation, CMML | 01/26 | 01/27 | | |
| Recruiting | 1 | 90 | Europe | NVG-111 | NovalGen Ltd. | Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma, Diffuse Large B Cell Lymphoma, Non-small Cell Lung Cancer (NSCLC), Malignant Melanoma | 12/23 | 12/25 | | |
NKX019-101, NCT05020678: NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers |
|
|
| Recruiting | 1 | 150 | US, RoW | NKX019 | Nkarta Inc. | Lymphoma, Non-Hodgkin, B-cell Acute Lymphoblastic Leukemia, Large B-cell Lymphoma, Mantle Cell Lymphoma, Indolent Lymphoma, Waldenstrom Macroglobulinemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Aggressive Lymphoma, Large-cell Lymphoma | 08/24 | 12/38 | | |
| Recruiting | 1 | 36 | US | KUR-502, CD19.CAR-aNKT cells | Athenex, Inc. | NHL, Relapsed, Adult, B-cell Lymphoma, B-cell Leukemia, DLBCL - Diffuse Large B Cell Lymphoma, ALL, Adult B Cell, ALL, Childhood, CLL/SLL | 12/23 | 12/24 | | |
CARDINAL, NCT06163430: - A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia |
|
|
| Not yet recruiting | 1 | 80 | US | TERN-701 | Terns, Inc. | Chronic Myeloid Leukemia, Chronic Phase, Chronic Myeloid Leukemia | 11/25 | 05/26 | | |
NCI-2014-01147, NCT02159495: Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm |
|
|
| Active, not recruiting | 1 | 31 | US | cyclophosphamide, CPM, CTX, Cytoxan, Endoxan, Endoxana, Autologous CD123CAR-CD28-CD3zeta-EGFRt-expressing T Lymphocytes, CD123R(EQ)28zeta/EGFRt+ T cells, Anti CD123-CAR/CD28-costimulatory Lentiviral Vector-transduced Autologous T Lymphocytes, laboratory biomarker analysis, Allogeneic CD123CAR-CD28-CD3zeta-EGFRt-expressing T-lymphocytes, Allogeneic CD123R(EQ)28zeta/EGFRt+ T Cells, Fludarabine Phosphate, 2-F-ara-AMP, 9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-.beta.-D-arabinofuranosyl)-, Beneflur, Fludara, Oforta, SH T 586 | City of Hope Medical Center, National Cancer Institute (NCI), Mustang Bio, Inc. | Adult Acute Myeloid Leukemia in Remission, Acute Biphenotypic Leukemia, Early Relapse of Acute Myeloid Leukemia, Late Relapse of Acute Myeloid Leukemia, Recurrent Adult Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Blastic Plasmacytoid Dendritic Cell Neoplasm, Acute Myeloid Leukemia, Adult Acute Lymphoblastic Leukemia, Interleukin-3 Receptor Subunit Alpha Positive, Minimal Residual Disease, Refractory Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia | 12/24 | 12/24 | | |
|
|
NCT02675452: AMG 176 First in Human Trial in Participants With Relapsed or Refractory Multiple Myeloma and Participants With Relapsed or Refractory Acute Myeloid Leukemia |
|
|
| Active, not recruiting | 1 | 142 | Europe, Canada, Japan, US, RoW | AMG 176, Study Investigational Product (IP), Azacitidine, Itraconazole | Amgen | Relapsed or Refractory Multiple Myeloma, Relapsed or Refractory Acute Myeloid Leukemia | 06/24 | 06/24 | | |
NCT04702425: VOB560-MIK665 Combination First in Human Trial in Patients With Hematological Malignancies (Relapsed/Refractory Non-Hodgkin Lymphoma, Relapsed/Refractory Acute Myeloid Leukemia, or Relapsed/Refractory Multiple Myeloma) |
|
|
| Active, not recruiting | 1 | 37 | Europe, Japan, US, RoW | VOB560, S65487, MIK665, S64315 | Novartis Pharmaceuticals | Non-Hodgkin Lymphoma (NHL), Acute Myeloid Leukemia (AML), Multiple Myeloma (MM) | 07/24 | 07/24 | | |
NCT05722171: Clinical Study of UTAA06 Injection in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia |
|
|
| Recruiting | 1 | 10 | RoW | gdT cell injection targeting B7-H3 chimeric antigen receptor, UTAA06 injection | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | Relapsed/Refractory Acute Myeloid Leukemia | 12/23 | 12/24 | | |
NCT04609826: A Study of JNJ-74856665 in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) |
|
|
| Active, not recruiting | 1 | 153 | Europe, RoW | JNJ-74856665, AZA, VEN | Janssen Research & Development, LLC | Acute Myeloid Leukemia, Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia | 07/24 | 07/24 | | |
| Active, not recruiting | 1 | 112 | Europe, US | RVU120(SEL120) | Ryvu Therapeutics SA | Acute Myeloid Leukemia, High-risk Myelodysplastic Syndrome | 12/24 | 12/24 | | |
| Active, not recruiting | 1 | 74 | RoW | APG-2575 | Ascentage Pharma Group Inc., Suzhou Yasheng Pharmaceutical Co., Ltd. | Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma | 12/24 | 12/25 | | |
| Active, not recruiting | 1 | 31 | US | Ruxolitinib, INCB-18424, INCB18424, Jakafi, Oral JAK Inhibitor INCB18424, Venetoclax, ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta, Venclyxto | Brian Druker, AbbVie, Incyte Corporation, Oregon Health and Science University | Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia | 12/24 | 12/24 | | |
NCT04220684: Trial Testing Safety of IL-21 NK Cells for Induction of R/R AML |
|
|
| Recruiting | 1 | 21 | US | Cytarabine Hydrochloride, Ara-C HCl, Arabinosylcytosine Hydrochloride, Aracytidine Hydrochloride, CHX-3311, Cytosar Hydrochloride, Cytosine Arabinosine Hydrochloride, U-19920A, Fludarabine, Fluradosa, Membrane-bound Interleukin-21-Expanded Haploidentical Natural Killer Cells, (mbIL21)-expanded Haploidentical NK Cells, Donor mbIL21-expanded NK Cells, mbIL21-expanded Haploidentical NK Cells | Sumithira Vasu, Kiadis Pharma | Allogeneic Stem Cell Transplant Recipient, Blasts 10 Percent or More of Bone Marrow Nucleated Cells, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia | 12/24 | 12/24 | | |
NCT05471323: Phase I Clinical Trial of RC1012 Injection in Patients With r/r AML |
|
|
| Recruiting | 1 | 36 | RoW | RC1012 injection (allo-DNT cells) | Guangdong Ruishun Biotech Co., Ltd, First Affiliated Hospital of Zhejiang University | Acute Myeloid Leukemia | 12/23 | 12/24 | | |
NCT05434312: TGRX-678 Chinese Phase I in Chronic Myelogenous Leukemia (CML) Patients |
|
|
| Recruiting | 1 | 90 | RoW | TGRX-678 | Shenzhen TargetRx, Inc., Peking University People's Hospital | Chronic Myelogenous Leukemia | 12/24 | 06/25 | | |
NCT04825496: Clinical Study of ssCART-19 Cells in Patients With CD19 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia |
|
|
| Recruiting | 1 | 18 | RoW | ssCART-19 Cells, Fludarabine, FA, Cyclophosphamide, CTX | Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd, The First Affiliated Hospital of Soochow University | Relapsed or Refractory Acute Lymphoblastic Leukemia | 12/23 | 12/24 | | |
NCT01976520: Vaccine Therapy for Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) |
|
|
| Active, not recruiting | 1 | 30 | US | Oncoquest-CLL vaccine, ATCE Vaccine, ATCEV, Autologous Tumor Vaccine, Oncoquest-CLL | XEME Biopharma Inc., National Cancer Institute (NCI) | Chronic Lymphocytic Leukemia (CLL) | 01/24 | 01/24 | | |
NCT03709758: Venetoclax in Combination With Intensive Induction and Consolidation Chemotherapy in Treatment Naïve AML |
|
|
| Recruiting | 1 | 64 | US | Venetoclax, Venclexta, Daunorubicin, Cerubidine, Cytarabine, Cytosar-U | Dana-Farber Cancer Institute, AbbVie, Genentech, Inc. | Acute Myeloid Leukemia | 07/24 | 06/25 | | |
NCT03533816: Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide |
|
|
| Recruiting | 1 | 38 | US | EAGD T-cell infusion (Phase I), CliniMACS-Prodigy, CliniMACS Alpha Beta T-Cell Depletion System, EAGD T-cell infusion (Expansion) | University of Kansas Medical Center, In8bio Inc. | Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes | 01/24 | 01/25 | | |
NCT04789408: Study of KITE-222 in Participants With Relapsed/Refractory Acute Myeloid Leukemia |
|
|
| Terminated | 1 | 15 | Europe, US | Cyclophosphamide, Fludarabine, KITE-222 | Kite, A Gilead Company | Acute Myeloid Leukemia | 05/24 | 05/24 | | |
NCT04996030: A Study for Oral SY-2101 for Participants With Acute Promyelocytic Leukemia |
|
|
| Suspended | 1 | 16 | US | SY-2101, Oral ATO, Oral Arsenic Trioxide, Arsenic Trioxide, IV ATO, Trisenox®, IV Arsenic Trioxide | Syros Pharmaceuticals | Acute Promyelocytic Leukemia | 01/24 | 04/24 | | |
COVALENT-101, NCT05153330: Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL |
|
|
| Recruiting | 1 | 177 | Europe, US | BMF-219, Covalent Menin Inhibitor | Biomea Fusion Inc. | Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Acute Mixed-Phenotype Leukemia, Cancer, Refractory, Progression, Diffuse Large B Cell Lymphoma, Multiple Myeloma, Lymphoma, Lymphoma, Non-Hodgkin, Myeloma, Plasma-Cell, Myelomatosis, Plasma Cell Myeloma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 12/24 | 03/25 | | |
NCT06146257: A Study of GLB-001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher Risk Myelodysplastic Syndromes |
|
|
| Recruiting | 1 | 48 | US | GLB-001, GLB-C183-A-2 | GluBio Therapeutics Inc. | Acute Myeloid Leukemia, Myelodysplastic Syndromes | 10/25 | 10/26 | | |
NCT04658004: NKG2D CAR-T Cell Therapy for Patients With Relapsed and/or Refractory Acute Myeloid Leukemia |
|
|
| Not yet recruiting | 1 | 36 | RoW | NKG2D CAR T-cells, NKG2D CAR-T cells injection | Zhejiang University, Yake Biotechnology Ltd. | Acute Myeloid Leukemia | 01/24 | 01/27 | | |
NCT04662294: CD 70 CAR T for Patients With CD70 Positive Malignant Hematologic Diseases |
|
|
| Recruiting | 1 | 108 | RoW | CD70 CAR T-cells, CD70 CAR-T cells injection | Zhejiang University, Yake Biotechnology Ltd. | Acute Myeloid Leukemia, Non-hodgkin's Lymphoma, Multiple Myeloma | 01/24 | 01/27 | | |
NCT06209671: INS19 CAR-T Cells for the Treatment of Relapsed or Refractory Acute B Lymphoblastic Leukemia |
|
|
| Not yet recruiting | 1 | 12 | NA | INS19 CAR-T Cells | Beijing Immunochina Medical Science & Technology Co., Ltd., Peking University People's Hospital | Leukemia, B-cell | 01/25 | 01/26 | | |
NCT05226468: An Early Phase Study of NEI-01 in Patients With Solid Tumors or Acute Myeloid Leukemia |
|
|
| Active, not recruiting | 1 | 24 | RoW | NEI-01 | New Epsilon Innovation Limited | Advanced Solid Tumor, Relapsed AML, Refractory AML | 01/24 | 07/24 | | |
FRIDA, NCT05546580: Study of Iadademstat and Gilteritinib in Patients With R/R AML With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+) |
|
|
| Recruiting | 1 | 50 | US | Iadademstat, ORY-1001, RO7051790, Gilteritinib Oral Tablet, XOSPATA® | Oryzon Genomics S.A. | Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory | 01/25 | 07/25 | | |
|
| Recruiting | 1 | 60 | RoW | XY0206 | Shijiazhuang Yiling Pharmaceutical Co. Ltd, Proswell Medical Corporation | Acute Myeloid Leukemia | 02/24 | 02/24 | | |
